Test ID: ACC    
Adrenal Mass Panel, 24 Hour, Urine

Aids in assessing malignancy in adrenal masses

May aid in improving diagnostic and prognostic prediction and dissect disease mechanisms for the following applications:

-Diagnostic assessment and follow up of adrenal cortical carcinoma (ACC)

-Differential diagnostic assessment of adrenal tumors

-Additional assessment related to Cushing syndrome, subclinical Cushing syndrome, primary aldosteronism, inborn errors of steroidogenesis, polycystic ovary syndrome

This test is not useful for establishing eligibility for a specific treatment as results must be interpreted in conjunction with the clinical status of the patient.

This test offers an accurate, rapid, cost-effective, non-invasive tool to better assess malignant adrenal tumors and assists clinicians in determining whether an adrenal mass is benign or malignant.

Testing begins with a clinical risk assessment based on clinical data before integration with biochemical steroid data to assess the probability of a malignant adrenal cortical carcinoma (ACC) or other malignancy (sarcoma, lymphoma, other) as well as the probability of a benign mass (adenoma, myelolipoma, cyst, other).

Clinical data includes age at diagnosis, gender, mode of discovery and hormonal status along with tumor diameter and an unenhanced CT density measurement of the tumor (in Hounsfield units).

Steroids and their metabolites are extracted, analyzed, quantitated, and reported. Each reported analyte also includes a Z-score. An integrated risk assessment based on clinical data in combination with biochemical steroid data is reported to assess the probability of a malignant ACC or other malignancy as well as the probability of a benign mass.

See Adrenal Mass Panel Clinical Data Definition of Malignancy Predictors in Special Instructions.

• Adrenal Mass Panel Clinical Data Definition of Malignancy Predictors
• Adrenal Mass Panel Patient Information

Liquid Chromatography-Tandem Mass Spectrometry, High-Resolution Accurate Mass (LC-MS/MS HRAM)